Data / Drug companies / Bausch Health US LLC
Bausch Health US LLC: 76 products in the FDA NDC directory, labeler code 0187
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Bausch Health US LLC (labeler code 0187) lists 76 products in the FDA National Drug Code Directory, covering 33 finished drugs by generic name. By type: 73 prescription drugs, 3 over the counter drugs. Its main marketing category is new drug applications (NDA). The newest product started marketing on October 20, 2023.
The request: Watch Bausch Health US LLC (FDA labeler code 0187): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 0187
- Products in commercial distribution
- 76
- Packages
- 129
- Finished drugs by generic name
- 33
- Prescription products
- 73
- Over the counter products
- 3
- Controlled substance products
- Schedule IV 3
- Flagged as original packager
- 75 of 75 products that carry the flag
- Started marketing in the last 12 months
- 0
- Products with a marketing end date set
- 3
- Earliest marketing start
- April 6, 1955
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| New drug applications (NDA) | 70 | 92.1% |
| Over the counter monograph drugs | 3 | 3.9% |
| Generic drugs (ANDA) | 2 | 2.6% |
| Biologics (BLA) | 1 | 1.3% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 73 | 96.1% |
| Over the counter drugs | 3 | 3.9% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Diltiazem hydrochloride | 20 | 55 |
| Tretinoin | 11 | 28 |
| Enalapril maleate | 4 | 32 |
| Lorazepam | 3 | 38 |
| Bupropion hydrobromide | 3 | 2 |
| Pyridostigmine bromide | 3 | 20 |
| Flucytosine | 2 | 10 |
| Bexarotene | 2 | 8 |
| Bupropion hydrochloride | 2 | 67 |
| Acyclovir | 2 | 70 |
| Famotidine | 2 | 138 |
| Dimethicone | 1 | 69 |
| Clindamycin phosphate and benzoyl peroxide | 1 | 14 |
| Trientine hydrochloride | 1 | 7 |
| Chlordiazepoxide hydrochloride and clidinium bromide | 1 | 13 |
| Selegiline hydrochloride | 1 | 12 |
| Metronidazole | 1 | 68 |
| Brodalumab | 1 | 1 |
| Acyclovir and hydrocortisone | 1 | 1 |
| Efinaconazole | 1 | 1 |
| Verteporfin for injection | 1 | 2 |
| Tolcapone | 1 | 3 |
| Tazarotene | 1 | 10 |
| Halobetasol propionate and tazarotene | 1 | 1 |
| Sulfacetamide sodium | 1 | 13 |
| Clindamycin phosphate/benzoyl peroxide/adapalene | 1 | 1 |
| Tetracaine hydrochloride | 1 | 9 |
| Erythromycin and benzoyl peroxide | 1 | 3 |
| Ferric oxide red, zinc oxide, and pramoxine hydrochloride | 1 | 1 |
| Pramoxine hydrochloride and zinc acetate | 1 | 9 |
| Halobetasol propionate | 1 | 11 |
| Enalapril maleate and hydrochlorothiazide | 1 | 3 |
| Fluorouracil | 1 | 21 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, extended release | 12 | 15.8% |
| Tablet | 9 | 11.8% |
| Cream | 9 | 11.8% |
| Gel | 9 | 11.8% |
| Lotion | 7 | 9.2% |
| Capsule, extended release | 6 | 7.9% |
| Capsule, coated, extended release | 5 | 6.6% |
| Capsule | 4 | 5.3% |
| Tablet, coated | 3 | 3.9% |
| Tablet, film coated | 3 | 3.9% |
| Solution | 2 | 2.6% |
| Tablet, orally disintegrating | 1 | 1.3% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Cabtreo | 0187-0006 | Gel | New drug applications (NDA) | October 20, 2023 |
| Arazlo | 0187-2098 | Lotion | New drug applications (NDA) | December 19, 2019 |
| Tetracaine Hydrochloride | 0187-0920 | Solution/ drops | New drug applications (NDA) | June 27, 2019 |
| Duobrii | 0187-0653 | Lotion | New drug applications (NDA) | April 25, 2019 |
| Bryhali | 0187-0002 | Lotion | New drug applications (NDA) | November 6, 2018 |
| Altreno | 0187-0005 | Lotion | New drug applications (NDA) | August 24, 2018 |
| Retin-A MICRO | 0187-5146 | Gel | New drug applications (NDA) | October 23, 2017 |
| Siliq | 0187-0004 | Injection | Biologics (BLA) | February 15, 2017 |
| Onexton | 0187-3050 | Gel | New drug applications (NDA) | November 24, 2014 |
| Tiazac extended release | 0187-2617 | Capsule, extended release | New drug applications (NDA) | August 20, 2014 |
| Tiazac extended release | 0187-2616 | Capsule, extended release | New drug applications (NDA) | August 20, 2014 |
| Tiazac extended release | 0187-2615 | Capsule, extended release | New drug applications (NDA) | August 20, 2014 |
| Tiazac extended release | 0187-2614 | Capsule, extended release | New drug applications (NDA) | August 20, 2014 |
| Tiazac extended release | 0187-2613 | Capsule, extended release | New drug applications (NDA) | August 20, 2014 |
| Tiazac extended release | 0187-2612 | Capsule, extended release | New drug applications (NDA) | August 20, 2014 |
| Jublia | 0187-5400 | Solution | New drug applications (NDA) | June 6, 2014 |
| Retin-A MICRO | 0187-5148 | Gel | New drug applications (NDA) | January 28, 2014 |
| Caladryl Clear | 0187-5466 | Lotion | Over the counter monograph drugs | August 16, 2013 |
| Caladryl | 0187-5465 | Lotion | Over the counter monograph drugs | August 16, 2013 |
| Noritate | 0187-5202 | Cream | New drug applications (NDA) | August 9, 2013 |
| Ativan | 0187-0065 | Tablet | New drug applications (NDA) | May 1, 2013 |
| Ativan | 0187-0064 | Tablet | New drug applications (NDA) | May 1, 2013 |
| Ativan | 0187-0063 | Tablet | New drug applications (NDA) | May 1, 2013 |
| TheraSeal | 0187-1660 | Cream | Over the counter monograph drugs | January 1, 2012 |
| Cardizem LA | 0187-2050 | Tablet, extended release | New drug applications (NDA) | December 25, 2010 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.